Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported routine equity activity involving company common stock. On June 30, 2026, he acquired 3,056 shares through the company’s Employee Stock Purchase Plan at $6.95 per share, a plan-based purchase described as exempt under Rule 16b-3.
On July 7, 2026, he sold 48,199 shares of common stock in an open-market transaction at a weighted average price of $19.58 per share, executed in multiple trades between $18.52 and $20.20 pursuant to a pre-established Rule 10b5-1 trading plan adopted on October 30, 2025. Following these transactions, Patel directly holds 615,898 shares of Relay Therapeutics common stock.
Separate from his direct holdings, irrevocable trusts for the benefit of his family members hold 687,355 shares and 199,548 shares of common stock, respectively, with an independent trustee. Patel disclaims beneficial ownership of the shares held in these trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 48,199 shares ($943,736)
Net Sell
4 txns
Insider
Patel Sanjiv
Role
President and CEO
Sold
48,199 shs ($944K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 48,199 | $19.58 | $944K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| Grant/Award | Common Stock | 3,056 | $6.95 | $21K |
Holdings After Transaction:
Common Stock — 615,898 shares (Direct, null);
Common Stock — 199,548 shares (Indirect, By The Patel Family Irrevocable Trust of 2019)
Footnotes (1)
- The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on January 2, 2026. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. This transaction was executed in multiple trades at prices ranging from $18.52 to $20.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 48,199 shares
Weighted average sale price: $19.58 per share
Shares acquired via ESPP: 3,056 shares
+4 more
7 metrics
Shares sold
48,199 shares
Open-market sale on July 7, 2026
Weighted average sale price
$19.58 per share
Common stock sale on July 7, 2026
Shares acquired via ESPP
3,056 shares
ESPP purchase on June 30, 2026
ESPP purchase price
$6.95 per share
85% of closing price on January 2, 2026
Direct holdings after transactions
615,898 shares
Common stock held directly after July 7, 2026 sale
Trust holdings (SSP Irrevocable Trust 2020
687,355 shares
Common stock held in family trust with independent trustee
Trust holdings (Patel Family Trust 2019)
199,548 shares
Common stock held in separate family trust
Key Terms
Employee Stock Purchase Plan, Rule 16b-3, Rule 10b5-1 trading plan, weighted average sale price, +2 more
6 terms
Employee Stock Purchase Plan financial
"The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3 regulatory
"in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"This transaction was executed in multiple trades at prices ranging from $18.52 to $20.20. The price reported above reflects the weighted average sale price."
irrevocable trusts financial
"These shares are held in irrevocable trusts for the benefit of the reporting person's family members."
beneficial ownership regulatory
"The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What insider transactions did Relay Therapeutics (RLAY) CEO Sanjiv Patel report?
Sanjiv Patel reported acquiring 3,056 Relay Therapeutics shares via the ESPP and selling 48,199 shares in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan and involved multiple trades within a disclosed price range.
Were the Relay Therapeutics (RLAY) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states that the 48,199-share sale on July 7, 2026, was effected pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025. Such pre-arranged plans schedule trades in advance to help separate them from short-term market timing decisions.